Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rigshospitalet, Denmark
Masonic Cancer Center, University of Minnesota
Caribou Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
AbbVie
Canadian Cancer Trials Group
Cedars-Sinai Medical Center
Eli Lilly and Company
Karyopharm Therapeutics Inc
Cancer Research UK
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Heidelberg Medical Center
Essen Biotech
M.D. Anderson Cancer Center
American Society of Clinical Oncology
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
GeoVax, Inc.
Memorial Sloan Kettering Cancer Center
AbbVie
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Wake Forest University Health Sciences
Colorado State University
University Hospital, Montpellier
Adela, Inc
Mayo Clinic
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Pfizer
VA Office of Research and Development
University of Nebraska
Zhongnan Hospital